What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
The T helper cell type 1 (Th1) response is essential to resist leishmaniasis, whereas the Th2 response favors the disease. However, many leishmanial antigens, which stimulate a Th1 immune response during the disease or even after the disease is cured, have been shown to have no protective action. Pa...
Main Author: | A. Campos-Neto |
---|---|
Format: | Article |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
2005-07-01
|
Series: | Brazilian Journal of Medical and Biological Research |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000700001&lng=en&tlng=en |
Similar Items
-
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
by: Campos-Neto A.
Published: (2005-01-01) -
Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection
by: Katherine M. Eichinger, et al.
Published: (2020-07-01) -
Adjuvants for Leishmania vaccines: From Models to Clinical Application
by: Vanitha S. Raman, et al.
Published: (2012-06-01) -
Cutaneous Leishmaniasis Vaccination: A Matter of Quality
by: Paula Mello De Luca, et al.
Published: (2016-04-01) -
INFLUENCE OF MICROBIOTA IN EXPERIMENTAL CUTANEOUS LEISHMANIASIS IN SWISS MICE
by: OLIVEIRA Marcia Rosa de, et al.
Published: (1999-01-01)